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Abstract
AIM
To assess circulatory levels of interleukin-18 (IL-18)
and determine whether the presence of IL-18 promoter
polymorphism influences metabolic syndrome phenotypes.

Institutional review board statement: This study was approved
by the institutional ethical committee and all participants gave a
written and informed consent to participate in this study.
Informed consent statement: Informed consent was obtained
prior to enrollment from all individual participants included in
the study.

METHODS
This study recruited one hundred and eighty individuals
divided into three groups with sixty subjects each as:
2
Normal weight (18.0-22.9 kg/m ), overweight (23.0-25.9
2
2
kg/m ) and obese (> 26.0 kg/m ) according to South
Asian criteria of BMI. Fasting blood glucose (FBG),
Lipid profile, insulin, IL-18 and tumor necrosis factor
(TNF)α were measured using ELISA kits, whereas low
density lipoprotein (LDL)-cholesterol, insulin resistance
(HOMA-IR) and insulin sensitivity (QUICKI) were
calculated. The body fat percentage (BF) was measured
through bioelectrical impedance analysis; waist and
hip circumference were measured. Genotyping of IL-18
-607 C/A polymorphism was performed by using tetraprimer amplification refractory mutation system. Student
t test, One-way analysis of variance, Hardy-Weinberg
2
equilibrium, Pearson’s χ test and Pearson’s correlation
were used, where a P value < 0.05 was considered
significant.
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RESULTS
In an aged matched study, obese subjects showed
higher levels of FBG, cholesterol, triglycerides and
LDL levels as compared to normal weight (P < 0.001).
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Highest levels of IL-18 and TNF levels were also seen
in obese subjects (IL-18: 58.87 ± 8.59 ng/L) (TNF:
4581.93 ± 2132.05 pg/mL). The percentage of IL-18
-607 A/A polymorphism was higher in overweight and
obese subjects vs normal weight subjects (P < 0.001).
Moreover, subjects with AA genotype had a higher
BF, insulin resistance, TNFa and IL-18 levels when
compared with subjects with AC (heterozygous) or CC
(wild type) genotypes. However, we did not find any
difference in the lipid profile between three subgroups.

healing mechanism, maintained in a fine balance.
However, it has been established that its over-production
[3]
results in autoimmune inflammatory disorders .
Apart from its role in inflammation, IL-18 has also
been associated with increased visceral adiposity and
obesity. Studies report abnormally elevated circulating
IL-18 levels in obese individuals while reduction in body
weight is found to results in a concomitant reduction
in IL-18 levels, supporting the fact that reduction in
adipose tissue leads to a decline in secretion of pro[4]
inflammatory cytokines . Furthermore, IL-18 mediated
inflammation is associated with cardiovascular disorders
[5]
suggesting its role in atherosclerotic diseases . In the
context of hyperglycemia, there are certain oxidative
mechanisms that increase circulating cytokines including
IL-18, thereby linking high blood glucose to the pro[6]
inflammatory cytokines . Various studies have reported
[7]
elevated serum IL-18 in patients with type 2 diabetes .
As the presence of risk factors for cardiovascular
disease and type 2 diabetes mellitus increases the
threat of developing metabolic syndrome (MetS),
IL-18 has been implicated to play a critical role in such
[8]
conditions . In terms of polymorphism in the IL-18
gene, various SNP are reported in association with
[9]
diseases like type 1 diabetes , chronic hepatitis B virus
[10]
[11]
infection , asthma .
The IL-18 gene is located on chromosome 11 (11
q22.2-22.3), and contains many polymorphism, especi
[12]
ally in the promoter region . One such polymorphism
is the -607 A/C that seems to affect the expression
[13]
level of IL-18 at transcription level . In addition, it has
been associated with the development of cardiovascular
disease such as vascular endothelial damage and forma
[14]
tion of atherosclerosis . The relationship between
the promoter region polymorphism of IL-18 and MetS
phenotypes is scarce. Therefore, we aimed to assess the
circulatory levels of IL-18 and determine whether the
presence of IL-18 promoter polymorphism influences
MetS phenotypes.

CONCLUSION
This preliminary data suggests that IL-18 polymorphism
affects IL-18 levels that might cause low grade inflam
mation, further exacerbated by increased TNFα. All
these increase the susceptibility to develop MetS.
Further studies are required to validate our findings.
Key words: Metabolic syndrome; Interleukin-18; Polymor
phism; Obesity; Body fat; High density lipoprotein; Low
density lipoprotein; Insulin
© The Author(s) 2017. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: Interleukin-18 (IL-18 ) gene polymorphisms
may influence the expression of its levels. This in
turn increases the risk of metabolic syndrome (MetS).
Therefore, we aimed to assess the circulatory levels
of IL-18 and determine whether the presence of IL-18
promoter polymorphism influences MetS phenotypes.
Subjects with AA genotype had a higher body fat, insulin
resistance, tumor necrosis factor α and IL-18 levels
when compared with subjects with AC (heterozygous) or
CC (wild type) genotypes. This preliminary data suggests
that IL-18 polymorphism affects IL-18 levels that might
cause low grade inflammation. All these increase the
susceptibility to develop MetS. Further studies are
required to validate our findings.
Fatima SS, Jamil Z, Abidi SH, Nadeem D, Bashir Z, Ansari
A. Interleukin-18 polymorphism as an inflammatory index in
metabolic syndrome: A preliminary study. World J Diabetes
2017; 8(6): 304-310 Available from: URL: http://www.
wjgnet.com/1948-9358/full/v8/i6/304.htm DOI: http://dx.doi.
org/10.4239/wjd.v8.i6.304

MATERIALS AND METHODS
Patient recruitment

This cross-sectional study recruited 180 healthy
male individuals from the waiting areas of outpatient
department of Aga Khan University. The subjects were
divided into three groups. Group A: normal weight
2
(18.0-22.9 kg/m ), Group B: overweight (23.0-25.9 kg/
2
2
m ), Group C: obese (> 26.0 kg/m ) according to South
[15]
Asian criteria of BMI . Subjects with diabetes mellitus,
hypertension [resting blood pressure (BP) 170/100
mmHg], dyslipidemia, body weight fluctuation of 5 kg in
the recent 6 mo, smokers, alcoholics, any acute illness
during last one month, as well as those taking antiinflammatory medications were excluded. This study
was approved by the institutional ethical committee and
all participants gave a written and informed consent to
participate in this study. The sample size was calculated

INTRODUCTION
Interleukin-18 (IL-18), also known as interferon-gamma
inducing factor, is a pro-inflammatory cytokine that
belongs to the IL-1 superfamily. It is not only produced
by immune cells like macrophages but is also express
by keratinocytes, osteoblasts cells, pituitary gland and
[1]
adrenal cortical cells . IL-18 serves as a mediator of
immune response by stimulating T-helper cells (Th-1)
[2]
against infections . In healthy individuals, its production
by the host is in line to utilization as a defense and
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in order to achieve 80% power to detect an odds ratio
of at least 2 among obese, with a two sided alpha value
of 95% (NCSS/PASS version 11 software for power
analysis and sample size).

Marker

CC

AA

CC

CC

CC

B

Anthropometric data

The weight and height of all the subjects were mea
sured in kilograms and meters respectively, using a
weight scale with a built-in Stadiometer (ZT-120 Health
Scale, Nanjing Everich China). Waist circumference
and hip circumference was measured using the WHO
[16]
protocol . Subjects were asked to stand in an erect
posture wearing light clothing. BMI was calculated by
2 [17]
dividing weight by height squared (kg/m ) . While
body fat percentage was measured using Diagnostic
Scale BG55 (Beurer Germany) through bioelectrical
impedance matching/analysis.

Figure 1 Genotype distribution of selected samples for the tetra arms
PCR. Marker is 100 bp DNA ladder and B is blank.

by the institutional ethical review board (3597-BBSERC-15), and all subjects gave a written and informed
consent.

Biochemical profile

Six milliliter of blood was collected from the study
participants after an overnight fast of 12 h. Fasting
plasma glucose and Lipid profile were measured using
commercially available kits as per the vendor’s instruction
(Merck, France). Low density lipoprotein (LDL)-cholesterol
[18]
levels were calculated using the Friedewald equation .
Fasting insulin, IL-18 and TNFα levels were measured
using an ELISA kit (DIA source Immuno Assay S.A.,
Belgium). Insulin resistance was calculated using the
homeostasis model assessment of insulin resistance
(HOMA-IR) index [fasting insulin (units per milliliter) ×
[19]
fasting glucose milligram/deciliter)/405] , and insulin
sensitivity was calculated by (QUICKI) {1/[log(fasting
[20]
insulin) + log(fasting glucose)]} .

Statistical analysis

A descriptive statistical analysis of continuous vari
ables was performed using SPSS (version 21; SPSS
Inc., Chicago, IL, United States). Data on continuous
variables were calculated as mean ± SD, whereas
data on categorical variables was presented as frequen
cies and percentages. Statistical comparisons were
computed using a student t test, one-way analysis
2
of variance (ANOVA) and Pearson’s χ test of indepen
dence. Pearson’s correlation (r) were used to determine
the correlation between serum IL-18 levels and lipid
profile, fasting blood glucose, insulin and body fat
parameters. Hardy-Weinberg equilibrium (HWE) was
calculated for IL-18 SNP. Significance and effect size of
minor allele with study parameters were determined
under an additive model of inheritance. In all statistical
analysis performed P values < 0.05 were considered
significant.

Genotyping

DNA extraction was performed using commercially
available Qiagen DNA extraction kit (Cat. #51185,
Valencia, CA United States). Genotyping of IL-18 -607
C/A polymorphism was performed by using tetra-primer
amplification refractory mutation system (TARMS-PCR)
®
using the GoTaq Hot Start Green Master Mix (Cat.
# M5122, Promega Corporation, United States) as
per the manufacturer’s instructions with the following
cycling conditions for PCR: 1 cycle for 5 min at 95 ℃
for initial denaturation followed by 35 cycles at 95 ℃
for 30 s, 55 ℃ for 30 s, 72 ℃ for 30 s followed by a
final extension of 10 min at 72 ℃. PCR products were
electrophoresed in 2% agarose gel. Genotyping quality
control was performed in 10% of the samples by
duplicate checking (rate of concordance in duplicates
was > 99 %). Tetra arms primers used for amplifying
IL-18 -607 (C/A) were as follows: Control Band (Outer
forward: CCTACAATGTTACAACACTTAAAAT; Outer
reverse: ATAAGCCCTAAATATATGTATCCTTA) (product
size 440 bp); A allele [Inner forward: GATACCA
TCATTAGAATTTTGTG (product size 278 bp)] and C allele
[Reverse inner GCAGAAAGTGTAAAAATTATCAA (product
Size 208 bp)] (Figure 1). The study was approved

WJD|www.wjgnet.com

RESULTS
Table 1 shows the biophysical and biochemical data
of the study subjects. All three groups were aged
matched, therefore no significant difference was
observed amongst the groups. Considerable difference
was observed in terms of raised BMI and BF in obese
group as compared to controls (P < 0.001). Similarly,
obese group had a higher FBG, insulin, cholesterol,
triglycerides and LDL levels as compared to controls
(P < 0.001). Interestingly no differences were seen in
the high density lipoprotein (HDL) levels of our study
groups. IL-18 and TNF levels showed an increasing
trend from normal weight to obese, with the highest
levels seen in obese group (IL-18: 58.87 ± 8.59) (TNF:
4581.93 ± 2132.05). We next performed the correlation
of IL-18 levels with the study parameters and report
a strong positive correlation of IL-18 with BMI, Waist
circumference, FBG, insulin, HOMA-IR, QUICKI, Choles
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Table 1 Biophysical and biochemical data of the study subjects
Variables

Age (yr)
BMI (kg/m2)
Body fat (%)
Waist circumference (cm)
Hip circumference (cm)
WHR (cm)
Fasting blood glucose (mg/dL)
Insulin (uIU/mL)
HOMA-IR
QUICKI
Cholesterol (mg/dL)
Triglyceride (mg/dL)
HDL(mg/dL)
LDL(mg/dL)
TNFα (pg/mL)
IL-18 (ng/L)

Normal weight
2
(18-22.9 kg/m )
(n = 60)

Overweight
2
(23-25.9 kg/m )
(n = 60)

Obese
2
(>26 kg/m )
(n = 60)

P value

26.21 ± 3.876
20.48 ± 1.30
19.26 ± 7.17
88.03 ± 10.53
77.69 ± 11.78
0.87 ± 0.05
89.31 ± 15.23
20.48 ± 7.95
4.70 ± 2.66
0.31 ± 0.02
145.72 ± 30.08
124.82 ± 43.92
39.96 ± 9.38
75.43 ± 30.03
810 ± 1233
25.34 ± 6.57

25.76 ± 4.059
24.20 ± 0.911
28.70 ± 9.101
88.46 ± 7.69
84.43 ± 0.69
0.871 ± 0.054
105.59 ± 12.501
34.96 ± 4.471
9.05 ± 1.341
0.27 ± 0.001
147.44 ± 37.91
137.58 ± 65.60
38.37 ± 8.00
79.57 ± 40.01
4455 ± 23901
41.96 ± 4.501

27.30 ± 5.389
28.59 ± 3.341,2
34.89 ± 4.471,2
1.9.26 ± 11.47
100.41 ± 12.89
0.91 ± 0.073
119.00 ± 25.711
41.13 ± 7.811,2
11.88 ± 2.811,2
0.27 ± 0.011
209.06 ± 55.511,2
167.03 ± 55.991,2
36.40 ± 6.40
134.78 ± 58.991,2
4581 ± 21321
58.87 ± 8.591,2

NS
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
NS
< 0.001
< 0.001
< 0.001

Values are expressed as mean ± SD. Comparison between groups was tested by One way analysis of variance followed by Tuckey’s post hoc test.
1
Statistically significant as compared to normal weight; 2Statistically significant as compared to overweight. Significance set at P value < 0.05. HOMAIR: Homeostasis model of insulin resistance; QUICKI: Quantitative insulin sensitivity check index; HDL: High density lipoprotein; LDL: Low density
lipoprotein; TNF: Tumor necrosis factor; WHR: Waist to hip ratio.

Table 2 Correlation of interleukin-18 with metabolic syndrome
phenotypes

Table 3 Genotype frequency among study subjects
Genotype distribution

Variable

Age (yr)
BMI (kg/m2)
Body fat (%)
Waist circumference (cm)
Hip circumference (cm)
Fasting blood glucose (mg/dL)
Insulin (uIU/mL)
HOMA-IR
QUICKI
Cholesterol (mg/dL)
LDL(mg/dL)
TNFα

Unadjusted r

Adjusted r
(age, BMI and
body fat %)

0.302
0.751
0.518
0.333
0.695
0.559
0.655
0.699
-0.600
0.514
0.464
0.577

---0.413
-0.110NS
0.376
0.205NS
0.344
-0.496
0.265
0.245
0.491

Normal weight
Overweight
Obese
Allele frequency
Normal weight
Overweight
Obese

AC
23
25
24

AA
10
24
24

P value
< 0.001

A allele
C allele
OR (95%CI)
P value
42 (35.0) 78 (65.0)
47 (39.17) 73 (60.83) 2.81 (1.66-4.68)1 < 0.001
48 (40.00) 72 (60.00) 2.91 (1.72-4.94)2

In all divisions the HWE was > 0.05. 1Normal weight vs overweight and
normal weight vs obese calculated by Pearson’s c 2 test. Allele frequencies
are given as absolute values with percentage given in parentheses.
2

compared with subjects with AC or CC genotypes.
However, we did not find any difference in the lipids
profile between three subgroups (Table 4).

Pearson Correlation was applied. All associations remained significant
after adjustment except insulin (NSnon-significant), statistically significant
P value < 0.01. HOMA-IR: Homeostasis model of insulin resistance;
QUICKI: Quantitative insulin sensitivity check index; LDL: Low density
lipoprotein; TNF: Tumor necrosis factor.

DISCUSSION
IL-18 is pleiotropic cytokine acting in both acquired and
innate immunity. Additionally it also acts to stimulate
[1]
the production of TNFα which is also a key player
[21,22]
associated with higher BMI
. These cytokines in turn
predispose an individual to develop MetS phenotypes.
In an age matched study group, we observed a
positive association of serum IL-18 concentration with
BMI, FBG, and serum TG, where body fat percentage
contributed most to the variation of serum IL-18
concentration. Furthermore, our study shows circulating
IL-18 levels were associated with measures of insulin
resistance (HOMA-IR) and decreased insulin sensitivity
(QUICKI) in apparently healthy obese subjects. Among
other factors causing a rise in IL-18 levels, nutritional

terol, and TNFα while a moderate correlation was
seen for LDL and BF. All these associations remained
significant after multiple adjustments for confounding
factors like age, BMI and BF, except insulin (Table 2 and
Figure 2).
The genotype distributions was in accordance
with HWE in total study subjects (P = 0.222) and in
subgroups (Normal Weight: P = 0.281; Overweight: P
= 0.663; Obese: P = 0.196). The percentage of IL-18
-607 A/A genotype was higher in overweight and obese
subjects vs normal weight subjects (P < 0.001 Table
3). Moreover, subjects with AA genotype had a higher
BF, insulin resistance, TNFα and IL-18 levels when

WJD|www.wjgnet.com

CC
27
11
12

307

June 15, 2017|Volume 8|Issue 6|

Fatima SS et al . IL-18 polymorphism and metabolic syndrome
Table 4 Stratification of study subjects according to genotype distribution
CC (n = 57)

AC (n = 72)

AA (n = 51)

23.36 ± 4.05
24.70 ±10.30
92.78 ± 16.61
74.18 ± 4.23
0.88 ± 0.069
103.41 ± 23.43
28.83 ± 11.91
7.75 ± 4.34
0.29 ± 0.02
161.01 ± 39.01
135.66 ± 42.29
38.29 ± 8.84
88.99 ± 5.38 (SEM)
2521 ± 353.9 (SEM)
37.16 ± 19.35

24.60 ± 4.137
28.70 ± 8.592
96.48 ± 13.21
67.40 ±3.99
0.88 ± 0.061
101.79 ± 21.01
32.76 ± 11.392
8.44 ± 3.71
0.28 ± 0.02
165.12 ± 55.03
145.61 ± 61.45
38.48 ± 56.32
94.73 ± 6.63 (SEM)
3403.08 ± 313.25 (SEM)
43.00 ± 13.192

25.25 ± 3.351
29.31 ± 9.461
97.32 ± 13.82
64.51 ± 4.84
0.89 ± 0.06
110.32 ± 21.97
34.67 ± 9.611
9.47 ± 3.001
0.28 ± 0.011
177.42 ± 60.72
146.78 ± 64.08
37.17 ± 6.75
107.77 ± 7.89 (SEM)
3760.35 ± 336.551 (SEM)
46.311 ± 13.071

Variables
BMI (kg/m2)
Body fat (%)
Waist circumference(cm)
Hip circumference (cm)
WHR (cm)
Fasting blood glucose (mg/dL)
Insulin (uIU/mL)
HOMA-IR
QUICKI
Cholesterol (mg/dL)
Triglyceride (mg/dL)
HDL(mg/dL)
LDL(mg/dL)
TNFα (pg/mL)
IL-18 (ng/L)

P value
0.05
< 0.001
0.085
0.694
0.490
> 0.05
0.002
0.007
0.046
> 0.05
> 0.05
> 0.05
> 0.05
0.008
0.001

1

AA vs CC; 2AC vs CC. HDL: High density lipoprotein; LDL: Low density lipoprotein; TNFα: Tumor necrosis factor alpha; IL-18: Interleukin-18.

100

in Chinese population reported a higher proportion of
A/A genotype in patients with type 2 diabetes, which is
somewhat similar to our report. Therefore, it is empirical
to identify the different genetic influences among
different races when considering genotype data and
risk association. For instance, A allele at position of -607
was a protective allele from type 1 diabetes in a Polish
[9]
population , while in a population from United Kingdom,
[27]
the significant association was not found .
These seemingly conflicting results suggested that
IL-18 probably acts as a feedback signal for obesity,
hyperglycemia, and positive energy balance. Alter
natively, it might be a consequence of sensitivity in
those subjects to the effect of IL-18. This may prove
that inflammatory marker (IL-18) may just not be an
indicator for chronic inflammation and obesity but has
a role in pathway leading to MetS. Another outcome of
our study was the relation of IL-18 with increased levels
of cholesterol and LDL. This opens up another avenue
about the role of IL-18 in atherosclerosis and presents a
great opportunity to work further in this field. Some of
previous studies have shown association of circulating
IL-18 levels with cardiovascular mortality among patients
[5]
with coronary artery disease . However, contrasting data
also exists which states no or weak association of IL-18
[28]
levels with BMI and lipid profile in European men , this
may suggest that association may vary according to the
population. In addition to Interleukin 18, recent repost
suggested that other variants such as Interleukin-23/
IL-17 axis has also been independently affiliated with
obesity in women especially related to increase visceral
[29]
fat, insulin resistance, and leptin levels
as well as
in causing hypertension and increased cardiovascular
[30]
risk .
One of the limitations of this study rests in the
study-design. As this was a cross sectional study the
association of IL-18 with all of these metabolic traits
could not be established, further more we were unable
to record the nonalcoholic fatty liver disease through

r = 0.518; P = 0.01

IL-18 levels (ng/L)

80
60
40
20
0

0

10

20

30

40

50

Body fat (%)

Figure 2 Correlation of interleukin-18 levels with body fat percentage.
IL-18: Interleukin-18.
[23]

states, such as hyperglycemia, and fat mass increase
have been validated the most. In particular, adipocytes
from obese individuals were found to secrete a threefold
[24]
higher IL-18 vs lean ones , identifying an essential
[25]
role of IL-18 in regulating fat distribution . Though,
an animal study demonstrated that deficiency of
IL-18 resulted in obesity and insulin resistance in mice
and the phenotype could be rescued by exogenous
[26]
administration of IL-18 .
We further evaluated the presence of a promote
gene polymorphism in these subjects. Interestingly,
we report that subjects with AA genotype had a higher
BMI, BF, insulin resistance and IL-18 levels. Moreover,
raised IL-18 increased the chances of developing
of MetS in our study subjects (OR = 2.72, 95%CI:
1.28-5.74, P = 0.008). Results regarding the association
of -607 SNP and MetS phenotypes are not consistent.
One study reported a decreased proportion of A/A
genotype in type 1 diabetic patients relative to control
[9]
[27]
subjects . However, another found higher proportion
of A/A genotype in type 1 diabetic patients but no risk
association could be identified. Another study, conducted

WJD|www.wjgnet.com
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ultra sonographic analysis. Nevertheless our results
clearly show that IL-18 can be used a marker for obesity
and supports the hypothesis that IL-18 may be involved
in pathway of MetS and form a link between metabolic
risk factors, diabetes, and cardiovascular diseases
specially in south Asian population.

8

9
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